|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
bisdemethoxycurcumin results in decreased activity of ABCC1 protein; curcumin III results in decreased activity of ABCC1 protein |
CTD |
PMID:15885658 PMID:16021489 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases activity |
ISO |
bisdemethoxycurcumin results in decreased activity of ABCC2 protein |
CTD |
PMID:15885658 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions decreases expression |
ISO |
bisdemethoxycurcumin results in increased phosphorylation of AKT1 protein AKT1 protein affects the reaction [bisdemethoxycurcumin results in increased expression of HMOX1 mRNA] [bisdemethoxycurcumin co-treated with Curcumin co-treated with demethoxycurcumin] inhibits the reaction [VEGF protein results in increased phosphorylation of AKT1 protein]; bisdemethoxycurcumin inhibits the reaction [VEGF protein results in increased phosphorylation of AKT1 protein] bisdemethoxycurcumin results in decreased expression of AKT1 protein modified form |
CTD |
PMID:17535857 PMID:35735092 PMID:35752269 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[bisdemethoxycurcumin analog co-treated with APP protein] results in increased expression of MGAT3 mRNA; [bisdemethoxycurcumin analog co-treated with APP protein] results in increased expression of TLR2 mRNA; [bisdemethoxycurcumin analog co-treated with APP protein] results in increased expression of TLR3 mRNA; [bisdemethoxycurcumin analog co-treated with APP protein] results in increased expression of TLR4 mRNA; [bisdemethoxycurcumin analog co-treated with APP protein] results in increased expression of VDR mRNA; [bisdemethoxycurcumin co-treated with APP protein] results in increased expression of MGAT3 mRNA; [bisdemethoxycurcumin co-treated with APP protein] results in increased expression of TLR2 mRNA; [bisdemethoxycurcumin co-treated with APP protein] results in increased expression of TLR3 mRNA; [bisdemethoxycurcumin co-treated with APP protein] results in increased expression of TLR4 mRNA; bisdemethoxycurcumin inhibits the reaction [APP protein binds to APP protein] |
CTD |
PMID:19715544 PMID:22029407 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO |
bisdemethoxycurcumin results in increased expression of CD36 mRNA bisdemethoxycurcumin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CD36 mRNA] |
CTD |
PMID:23386263 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
bisdemethoxycurcumin results in decreased expression of EGFR protein modified form |
CTD |
PMID:35735092 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
increases response to substance decreases expression |
ISO |
ERBB2 protein results in increased susceptibility to bisdemethoxycurcumin bisdemethoxycurcumin results in decreased expression of ERBB2 protein |
CTD |
PMID:34291863 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
bisdemethoxycurcumin results in increased expression of GCLM mRNA; bisdemethoxycurcumin results in increased expression of GCLM protein |
CTD |
PMID:17535857 PMID:19188863 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
decreases expression |
ISO |
bisdemethoxycurcumin results in decreased expression of GRB2 protein |
CTD |
PMID:35735092 |
|
NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
bisdemethoxycurcumin results in increased expression of HMOX1 mRNA; bisdemethoxycurcumin results in increased expression of HMOX1 protein [demethoxycurcumin co-treated with bisdemethoxycurcumin] results in increased expression of HMOX1 mRNA; AKT1 protein affects the reaction [bisdemethoxycurcumin results in increased expression of HMOX1 mRNA]; KEAP1 protein inhibits the reaction [bisdemethoxycurcumin results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [bisdemethoxycurcumin results in increased expression of HMOX1 mRNA]; PRKCD protein affects the reaction [bisdemethoxycurcumin results in increased expression of HMOX1 mRNA]; rottlerin inhibits the reaction [bisdemethoxycurcumin results in increased expression of HMOX1 mRNA]; rottlerin inhibits the reaction [bisdemethoxycurcumin results in increased expression of HMOX1 protein]; Wortmannin inhibits the reaction [bisdemethoxycurcumin results in increased expression of HMOX1 mRNA]; Wortmannin inhibits the reaction [bisdemethoxycurcumin results in increased expression of HMOX1 protein] |
CTD |
PMID:17535857 PMID:19188863 PMID:23386263 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
bisdemethoxycurcumin inhibits the reaction [Freund's Adjuvant results in increased secretion of IL1B protein] bisdemethoxycurcumin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:38056805 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
bisdemethoxycurcumin inhibits the reaction [Freund's Adjuvant results in increased secretion of IL6 protein] bisdemethoxycurcumin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:38056805 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
ISO |
[bisdemethoxycurcumin co-treated with Curcumin co-treated with demethoxycurcumin] inhibits the reaction [VEGF protein results in increased phosphorylation of KDR protein]; bisdemethoxycurcumin inhibits the reaction [VEGF protein results in increased phosphorylation of KDR protein] |
CTD |
PMID:35752269 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
KEAP1 protein inhibits the reaction [bisdemethoxycurcumin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:17535857 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions decreases expression |
ISO |
bisdemethoxycurcumin results in increased phosphorylation of MAPK1 protein [bisdemethoxycurcumin co-treated with Curcumin co-treated with demethoxycurcumin] inhibits the reaction [VEGF protein results in increased phosphorylation of MAPK1 protein]; bisdemethoxycurcumin inhibits the reaction [VEGF protein results in increased phosphorylation of MAPK1 protein] bisdemethoxycurcumin results in decreased expression of MAPK1 protein modified form |
CTD |
PMID:17535857 PMID:35735092 PMID:35752269 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions decreases expression |
ISO |
bisdemethoxycurcumin results in increased phosphorylation of MAPK3 protein [bisdemethoxycurcumin co-treated with Curcumin co-treated with demethoxycurcumin] inhibits the reaction [VEGF protein results in increased phosphorylation of MAPK3 protein]; bisdemethoxycurcumin inhibits the reaction [VEGF protein results in increased phosphorylation of MAPK3 protein] bisdemethoxycurcumin results in decreased expression of MAPK3 protein modified form |
CTD |
PMID:17535857 PMID:35735092 PMID:35752269 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mgat3 |
beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase |
multiple interactions increases expression |
ISO |
[bisdemethoxycurcumin analog co-treated with APP protein] results in increased expression of MGAT3 mRNA; [bisdemethoxycurcumin co-treated with APP protein] results in increased expression of MGAT3 mRNA bisdemethoxycurcumin results in increased expression of MGAT3 mRNA |
CTD |
PMID:19090986 PMID:22029407 |
|
NCBI chr 7:111,708,353...111,761,825
Ensembl chr 7:111,675,730...111,762,026
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
decreases expression |
ISO |
bisdemethoxycurcumin results in decreased expression of MMP14 protein |
CTD |
PMID:18495463 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
ISO |
bisdemethoxycurcumin results in decreased secretion of and results in decreased activity of MMP2 protein modified form bisdemethoxycurcumin results in decreased expression of MMP2 protein |
CTD |
PMID:18495463 PMID:35735092 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
bisdemethoxycurcumin results in decreased secretion of and results in decreased activity of MMP9 protein bisdemethoxycurcumin results in decreased expression of MMP9 protein |
CTD |
PMID:18495463 PMID:35735092 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
multiple interactions |
ISO |
bisdemethoxycurcumin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MSR1 mRNA] |
CTD |
PMID:23386263 |
|
NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization multiple interactions |
ISO |
bisdemethoxycurcumin affects the localization of NFE2L2 protein [demethoxycurcumin co-treated with bisdemethoxycurcumin] affects the localization of NFE2L2 protein; NFE2L2 protein affects the reaction [bisdemethoxycurcumin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:17535857 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO EXP |
bisdemethoxycurcumin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKB1 protein] bisdemethoxycurcumin inhibits the reaction [Freund's Adjuvant results in increased phosphorylation of NFKB1 protein] |
CTD |
PMID:38056805 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO EXP |
bisdemethoxycurcumin inhibits the reaction [Lipopolysaccharides results in decreased expression of NFKBIA protein]; bisdemethoxycurcumin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased degradation of NFKBIA protein] bisdemethoxycurcumin inhibits the reaction [Freund's Adjuvant results in decreased expression of NFKBIA protein] |
CTD |
PMID:18449507 PMID:38056805 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
bisdemethoxycurcumin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; bisdemethoxycurcumin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:18449507 PMID:18481332 PMID:18838107 PMID:19188055 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
bisdemethoxycurcumin results in increased expression of NQO1 mRNA; bisdemethoxycurcumin results in increased expression of NQO1 protein |
CTD |
PMID:17535857 PMID:19188863 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pdpk1 |
3-phosphoinositide dependent protein kinase-1 |
decreases expression |
ISO |
bisdemethoxycurcumin results in decreased expression of PDPK1 protein modified form |
CTD |
PMID:35735092 |
|
NCBI chr10:13,105,435...13,182,664
Ensembl chr10:13,105,498...13,174,623
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases secretion |
ISO |
bisdemethoxycurcumin results in decreased secretion of PLAU protein |
CTD |
PMID:18495463 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding |
ISO |
bisdemethoxycurcumin binds to PPARG protein |
CTD |
PMID:15713005 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
PRKCD protein affects the reaction [bisdemethoxycurcumin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:17535857 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO EXP |
bisdemethoxycurcumin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; bisdemethoxycurcumin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein] bisdemethoxycurcumin inhibits the reaction [Freund's Adjuvant results in increased expression of PTGS2 protein] |
CTD |
PMID:18449507 PMID:38056805 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
decreases expression |
ISO |
bisdemethoxycurcumin results in decreased expression of RAF1 protein modified form |
CTD |
PMID:35735092 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Sos1 |
SOS Ras/Rac guanine nucleotide exchange factor 1 |
decreases expression |
ISO |
bisdemethoxycurcumin results in decreased expression of SOS1 protein |
CTD |
PMID:35735092 |
|
NCBI chr 6:14,533,870...14,613,348
Ensembl chr 6:14,533,360...14,611,107
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression |
ISO |
bisdemethoxycurcumin results in decreased expression of TIMP1 protein |
CTD |
PMID:35735092 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
decreases expression |
ISO |
bisdemethoxycurcumin results in decreased expression of TIMP2 protein |
CTD |
PMID:18495463 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions |
ISO |
[bisdemethoxycurcumin analog co-treated with APP protein] results in increased expression of TLR2 mRNA; [bisdemethoxycurcumin co-treated with APP protein] results in increased expression of TLR2 mRNA |
CTD |
PMID:22029407 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tlr3 |
toll-like receptor 3 |
multiple interactions |
ISO |
[bisdemethoxycurcumin analog co-treated with APP protein] results in increased expression of TLR3 mRNA; [bisdemethoxycurcumin co-treated with APP protein] results in increased expression of TLR3 mRNA |
CTD |
PMID:22029407 |
|
NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[bisdemethoxycurcumin analog co-treated with APP protein] results in increased expression of TLR4 mRNA; [bisdemethoxycurcumin co-treated with APP protein] results in increased expression of TLR4 mRNA |
CTD |
PMID:22029407 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
bisdemethoxycurcumin inhibits the reaction [Freund's Adjuvant results in increased secretion of TNF protein]; bisdemethoxycurcumin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; bisdemethoxycurcumin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] bisdemethoxycurcumin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:18838107 PMID:38056805 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions |
ISO |
[bisdemethoxycurcumin analog co-treated with APP protein] results in increased expression of VDR mRNA |
CTD |
PMID:22029407 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[bisdemethoxycurcumin co-treated with Curcumin co-treated with demethoxycurcumin] inhibits the reaction [VEGF protein results in increased phosphorylation of AKT1 protein]; [bisdemethoxycurcumin co-treated with Curcumin co-treated with demethoxycurcumin] inhibits the reaction [VEGF protein results in increased phosphorylation of KDR protein]; [bisdemethoxycurcumin co-treated with Curcumin co-treated with demethoxycurcumin] inhibits the reaction [VEGF protein results in increased phosphorylation of MAPK1 protein]; [bisdemethoxycurcumin co-treated with Curcumin co-treated with demethoxycurcumin] inhibits the reaction [VEGF protein results in increased phosphorylation of MAPK3 protein]; bisdemethoxycurcumin inhibits the reaction [VEGF protein results in increased phosphorylation of AKT1 protein]; bisdemethoxycurcumin inhibits the reaction [VEGF protein results in increased phosphorylation of KDR protein]; bisdemethoxycurcumin inhibits the reaction [VEGF protein results in increased phosphorylation of MAPK1 protein]; bisdemethoxycurcumin inhibits the reaction [VEGF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:35752269 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wt1 |
WT1 transcription factor |
decreases expression |
ISO |
bisdemethoxycurcumin results in decreased expression of WT1 mRNA; bisdemethoxycurcumin results in decreased expression of WT1 protein |
CTD |
PMID:18034345 |
|
NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643
|
|